Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04807335Phase 1Completed

Study of CT001 in Healthy Volunteers

Role: collaborator

NCT04594577Not ApplicableCompleted

Clinical Validation of the Fluispotter System for Serial Sampling of Venous Dried Blood Spots

Role: collaborator

NCT03199872Phase 1Completed

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

Role: collaborator

All 3 trials loaded